---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-300538"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:32:41.728795+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone

## Summary
- Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.
- Cash awards: $399K (CEO), $170K (CFO), $250K (CMO); 50% paid upon TSC-101 pivotal trial milestone, 50% on first anniversary.
- Equity awards: 1M RSUs (CEO), 270K RSUs (CFO), 650K RSUs (CMO) granted upon milestone; vest 25% at year 2, 75% at trial completion or year 4.
- Awards subject to continued employment and terms of 2021 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-25-300538
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/0001193125-25-300538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/d41366d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-300538
- JSON: https://secwatch.observer/filing/0001193125-25-300538.json
- Plain text: https://secwatch.observer/filing/0001193125-25-300538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.